Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zapping the brain to curb meth cravings: new trial launches

NCT ID NCT07479771

Disease control Sponsor: Shanghai Mental Health Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 03, 2026 · Updated 4 times

Summary

This study tests a non-invasive brain stimulation technique called targeted temporal interference stimulation (tTIS) aimed at the caudate nucleus. The goal is to reduce drug cravings and improve decision-making in 60 adults with methamphetamine use disorder. Participants will receive the stimulation and be monitored for changes in craving, impulsivity, and reward learning over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

53 people

The number who actually took part.

Started

Mar 2026

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals aged between 18 and 55 years, irrespective of gender, having completed a minimum of 6 years of education and capable of effectively cooperating in questionnaire evaluations. * Meet the diagnostic criteria set forth by the DSM-V concerning the amphetamine-type substance addiction. * A history of utilizing amphetamine-type substances for a duration not less than one year, with a frequency of use being at least once per week. * Consent to actively cooperate in the completion of subsequent follow-up assessments. Exclusion Criteria: * Severe cognitive functional impairments manifested through a history of head trauma, cerebrovascular diseases, epilepsy, etc., or usage of cognitive enhancement drugs in the past 6 months; an intellectual disability with an IQ score less than 70. * A diagnosis of schizophrenia or other severe mental illnesses as per the DSM-5 criteria. * Abuse or dependence on other psychoactive substances (excluding nicotine) within the past 5 years. * Severe organic diseases that might compromise study participation. * Contraindications to cTBS, such as a history of epileptic seizures or the presence of metallic implants in proximity to the head.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Amphetamine use disorders are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amphetamine abuse methamphetamine dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Amphetamine use disorders

Contacts and locations

Locations

  • Shanghai Mental Health Center

    Shanghai, Shanghai, Shanghai, China, 200000, 200030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.